相似文献
1
Plasma fibrinolysis inhibitor levels in acute stroke patients with thrombolysis failure.
J Clin Neurol. 2005 Oct;1(2):142-7. doi: 10.3988/jcn.2005.1.2.142. Epub 2005 Oct 20.
2
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
J Thromb Haemost. 2007 Sep;5(9):1862-8. doi: 10.1111/j.1538-7836.2007.02665.x.
3
Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator.
Thromb Haemost. 2004 Jun;91(6):1146-51. doi: 10.1160/TH04-02-0097.
4
Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Thromb Res. 2006;118(2):189-97. doi: 10.1016/j.thromres.2005.06.014. Epub 2005 Aug 1.
5
Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Clin Appl Thromb Hemost. 2010 Oct;16(5):568-73. doi: 10.1177/1076029609350890. Epub 2009 Dec 2.
6
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2008 Sep;20(9):912-6. doi: 10.1097/MEG.0b013e3282faa759.
7
8
Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
Stroke. 2004 Sep;35(9):2123-7. doi: 10.1161/01.STR.0000137608.73660.4c. Epub 2004 Jul 8.
9
Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
Cerebrovasc Dis. 2016;42(5-6):404-414. doi: 10.1159/000447722. Epub 2016 Jul 8.
10
The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Blood Coagul Fibrinolysis. 2011 Sep;22(6):493-8. doi: 10.1097/MBC.0b013e328346f8ca.
引用本文的文献
1
A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
Adv Healthc Mater. 2022 Oct;11(19):e2201265. doi: 10.1002/adhm.202201265. Epub 2022 Jul 31.
2
Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.
Sci Adv. 2021 Jun 2;7(23). doi: 10.1126/sciadv.abf9033. Print 2021 Jun.
3
Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
Int J Mol Sci. 2021 Feb 2;22(3):1472. doi: 10.3390/ijms22031472.
4
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883.
5
Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620935207. doi: 10.1177/1076029620935207.
6
PAI-1 5G/5G genotype is an independent risk of intracranial hemorrhage in post-lysis stroke patients.
Ann Clin Transl Neurol. 2019 Nov;6(11):2240-2250. doi: 10.1002/acn3.50923. Epub 2019 Oct 21.
7
Engineered microparticles and nanoparticles for fibrinolysis.
J Thromb Haemost. 2019 Dec;17(12):2004-2015. doi: 10.1111/jth.14637. Epub 2019 Oct 7.
8
Markers of Coagulation and Fibrinolysis Predicting the Outcome of Acute Ischemic Stroke Thrombolysis Treatment: A Review of the Literature.
Front Neurol. 2019 Jun 21;10:513. doi: 10.3389/fneur.2019.00513. eCollection 2019.
9
The neurovascular unit and combination treatment strategies for stroke.
Trends Pharmacol Sci. 2012 Aug;33(8):415-22. doi: 10.1016/j.tips.2012.04.006. Epub 2012 May 16.
10
Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke.
Horm Behav. 2013 Feb;63(2):238-53. doi: 10.1016/j.yhbeh.2012.04.007. Epub 2012 Apr 24.
本文引用的文献
1
Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial.
Stroke. 2005 Jul;36(7):1432-8. doi: 10.1161/01.STR.0000171066.25248.1d. Epub 2005 Jun 16.
2
Association between platelet activation and fibrinolysis in acute stroke patients.
Neurosci Lett. 2005 Aug 26;384(3):305-9. doi: 10.1016/j.neulet.2005.04.090.
3
Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial.
Stroke. 2005 Apr;36(4):880-90. doi: 10.1161/01.STR.0000157668.39374.56. Epub 2005 Feb 24.
4
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
AJNR Am J Neuroradiol. 2004 Oct;25(9):1470-5.
5
Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator.
Thromb Haemost. 2004 Jun;91(6):1146-51. doi: 10.1160/TH04-02-0097.
6
Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study.
Neurology. 2003 May 27;60(10):1684-7. doi: 10.1212/01.wnl.0000063323.23493.98.
7
Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure.
Stroke. 2003 Jun;34(6):e48-50. doi: 10.1161/01.STR.0000073788.81170.1C. Epub 2003 May 15.
8
9
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):867-73. doi: 10.1161/01.atv.0000015445.22243.f4.
10
The fibrinolysis system: regulation of activity and physiologic functions of its main components.
Biochemistry (Mosc). 2002 Jan;67(1):99-108. doi: 10.1023/a:1013960416302.
Zotero 插件